Skip to main content
SpringerLink
Log in

Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study

  • Short Research Report
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Pharmacotherapy is the first line treatment for adult attention deficit hyperactivity disorder (ADHD) and the percentage of treated patients may indicate the quality of treatment of adult ADHD. The main aim of this study was to investigate the rates of pharmacological treatment for adult ADHD in Slovenia from 2003 to 2015. Methods The number of prescriptions per patient was obtained for three different age groups (18–24, 25–49, 50 + age group). The national consumption rates were obtained from the national database. The only drugs that were available and were included in this study were methylphenidate (MPH) and atomoxetine (ATX). Results Between 2003 and 2015 the rate of patients aged 18–24 who were treated with MPH increased from 0.8 per 10,000 people aged 18–24 to 8.9 per 10,000 people, while the increase in the other two age groups was less substantial (25–49, 50 + age group). The rate of patients aged 18–24 treated with ATX in 2015 was 7.3 per 10,000 people and 2.2 per 10,000 people in the 25–49 age category and 0.28 in the 50 + age group category. Conclusion Prescription rates of ADHD medication have increased dramatically in the study period. The high proportion of ADHD patients treated with ATX can be explained by low adherence to treatment guidelines. This is the first study to compare ADHD pharmacotherapy across different adult age groups in this part of Europe, so the results could be widely relevant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Akutagava-Martins GC, Rohde LA, Hutz MH. Genetics of attention-deficit/hyperactivity disorder: an update. Expert Rev Neurother. 2016;16:145–56.

    Article  CAS  PubMed  Google Scholar 

  2. Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56:345–65.

    Article  PubMed  Google Scholar 

  3. Štuhec M, Švab V, Locatelli I. Prevalence and incidence of attention-deficit/hyperactivity disorder in Slovenian children and adolescents: a database study from a national perspective. Croat Med J. 2015;56:159–65.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Stuhec M. Pharmacotherapy of ADHD in Slovenia: realities and perspectives. Eur Child Adolesc Psychiatry. 2016;25:455–7.

    Article  PubMed  Google Scholar 

  5. Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:179–203.

    Article  PubMed  Google Scholar 

  6. Stuhec M, Munda B, Svab V, Locatelli I. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord. 2015;178:149–59.

    Article  CAS  PubMed  Google Scholar 

  7. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T. 2009;34:678–94.

    PubMed  PubMed Central  Google Scholar 

  8. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med. 2006;8:4.

    Google Scholar 

  9. Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. Curr Med Res Opin. 2014;30:1673–85.

    Article  CAS  PubMed  Google Scholar 

  10. Štuhec M, Locatelli I, Švab V. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in slovenia from 2001 to 2012: a drug use study from a national perspective. J Child Adolesc Psychopharmacol. 2015;25:254–9.

    Article  PubMed  Google Scholar 

  11. Schubert I, Köster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Dtsch Arztebl Int. 2010;107:615–21.

    PubMed  PubMed Central  Google Scholar 

  12. Renoux C, Shin JY, Dell’Aniello S, Fergusson E, Suissa S. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995–2015. Br J Clin Pharmacol. 2016;82:858–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate-or extended-release methylphenidate or atomoxetine in the Netherlands during 2001–2006. J Child Adolesc Psychopharmacol. 2010;20:55–61.

    Article  PubMed  Google Scholar 

  14. Stuhec M, Locatelli I. Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: a population-based study. Eur Psychiatry. 2017;42:129–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Clinical Pharmacy Department, Ormož Psychiatric Hospital, Ptujska Cesta 33, 2270, Ormož, Slovenia

    Matej Stuhec

  2. Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia

    Matej Stuhec & Igor Locatelli

Authors
  1. Matej Stuhec
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Igor Locatelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matej Stuhec.

Ethics declarations

Conflicts of interest

The authors have no personal affiliations, financial relationship or any commercial interest to disclose relative to this article. The submitted report or any essential part of it is not published or simultaneously submitted to other publications prior to its appearance in this Journal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stuhec, M., Locatelli, I. Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study. Int J Clin Pharm 40, 341–344 (2018). https://doi.org/10.1007/s11096-018-0605-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-018-0605-0

Keywords

Search

Navigation